Related Experiment Video

Updated: May 7, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

MCP-1-2518A>G polymorphism and myocardial infarction risk: a meta-analysis and meta-regression

Bin Mao1, Jianqun Zhang, Fengling Zhuo

  • 11 Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University , Beijing, People's Republic of China .

Genetic Testing and Molecular Biomarkers
|September 24, 2013
PubMed
Abstract

Insights

The MCP-1 gene's -2518A>G polymorphism increases myocardial infarction (MI) risk, particularly in Asian populations. This finding clarifies previous inconclusive results on the genetic link between MCP-1 and MI susceptibility.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Biology and Inflammation

Background:

  • Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine in atherosclerotic inflammation and myocardial infarction (MI) development.
  • The common MCP-1 gene polymorphism (-2518A>G; rs1024611) has been investigated for its association with MI risk, but individual study results are inconclusive.

Purpose of the Study:

  • To conduct a meta-analysis to precisely estimate the association between the MCP-1-2518A>G polymorphism and susceptibility to myocardial infarction.
  • To clarify the role of this genetic variation in MI etiology.

Main Methods:

  • A comprehensive literature search was performed across PubMed, Embase, Web of Science, and CBM databases for studies published before May 15th, 2013.
  • Eleven case-control studies comprising 2325 MI patients and 6310 healthy controls were included.
  • Crude odds ratios with 95% confidence intervals were calculated to assess the association.

Main Results:

  • The meta-analysis revealed that the MCP-1-2518A>G polymorphism is associated with an increased risk of MI.
  • Subgroup analysis by ethnicity showed a significant association in Asian populations but not in Caucasian populations.
  • Meta-regression indicated that ethnicity is a major source of heterogeneity, with no detected publication bias.

Conclusions:

  • The MCP-1-2518A>G polymorphism is a potential risk factor for myocardial infarction.
  • The association is particularly significant among Asian populations, highlighting ethnic differences in genetic susceptibility to MI.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...